Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O43688

UPID:
PLPP2_HUMAN

ALTERNATIVE NAMES:
Lipid phosphate phosphohydrolase 2; PAP2-gamma; Phosphatidate phosphohydrolase type 2c; Phosphatidic acid phosphatase 2c

ALTERNATIVE UPACC:
O43688; A6NLV0; E9PAY8

BACKGROUND:
Phospholipid phosphatase 2, also referred to as PAP2-gamma or Phosphatidate phosphohydrolase type 2c, is an intracellular enzyme with a pivotal function in the dephosphorylation of glycerolipid and sphingolipid phosphate esters. Its activity on bioactive lipid mediators like phosphatidate and sphingosine 1-phosphate plays a significant role in generating new bioactive compounds, which are crucial for various cellular processes including signal transduction.

THERAPEUTIC SIGNIFICANCE:
The exploration of Phospholipid phosphatase 2's function offers a promising avenue for the development of novel therapeutic approaches. Given its central role in producing bioactive compounds and regulating signal transduction, targeting this enzyme could provide innovative treatments for conditions associated with altered lipid signaling pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.